An open-label first-in-human single ascending dose study to explore the safety, tolerability and efficacy of subretinal administration of CPK850 gene therapy in patients with retinitis pigmentosa caused by mutations in the RLBP1 gene
This research study is investigating a new treatment called CPK850, which is a type of gene therapy. It's designed for people with retinitis pigmentosa, an inherited eye disease that can lead to severe vision loss, specifically when it's caused by particular changes in the RLBP1 gene. This is the very first time this treatment is being given to humans, so it's mainly focused on safety. Researchers want to see if CPK850 is safe to use and how well people tolerate it. They will also be looking for any signs that it might help improve vision, especially how well people adapt to dim light. The study is in its early stages (Phase 1 and 2 combined) and involves giving the treatment directly into the eye.
At a glance
What is this study about?
You're reading about a new research study that's looking into a potential treatment for an eye condition called retinitis pigmentosa. This condition is inherited and gradually causes vision to get worse, often leading to difficulty seeing in dim light and eventually impacting central vision. This particular study is for people whose retinitis pigmentosa is caused by specific changes in a gene called RLBP1.
The new treatment being tested is called CPK850 gene therapy. Think of gene therapy like a very precise way of trying to fix a problem at its source. In this case, it aims to deliver a healthy copy of the RLBP1 gene into the eye, hoping to improve how the light-sensing cells in your eye (called photoreceptors) work. Since this is the first time CPK850 is being given to people, the main goal is to carefully check if it is safe and how well people tolerate it. Researchers will also be looking for any signs that your vision might improve.
Researchers will closely monitor whether the treatment causes any unwanted reactions and will also look at different aspects of your vision. This includes how long it takes for your eyes to adjust to darkness, how well you can see details, and your overall quality of life related to vision. The findings from studies like this are crucial because they help us understand if new treatments can be a safe and effective option for people living with these challenging eye conditions.
Key takeaways
- Tests CPK850 gene therapy for retinitis pigmentosa caused by a specific gene (RLBP1).
- This is the first human trial, focusing on safety and tolerability.
- Aims to improve vision, particularly how eyes adapt to darkness.
- Participation involves a single treatment and regular check-ups over about a year.
- Potential benefits include vision improvement, but risks and side effects are possible.
Who may be eligible?
To be able to take part in this study, you would need to meet certain requirements. The study is open to both men and women, and you must be at least 18 years old – there's no upper age limit mentioned.
Crucially, your retinitis pigmentosa must be clearly diagnosed and confirmed to be caused by changes in the RLBP1 gene. The study wants to make sure that the treatment being tested is appropriate for your specific type of the condition.
There will be other detailed checks that only a medical professional can confirm, to make sure the study is a good fit for you and that taking part would be safe. If you're interested, your doctor can help you understand all the eligibility criteria.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Are you at least 18 years old?
- Has your retinitis pigmentosa been confirmed by a doctor?
- Has genetic testing shown changes in your RLBP1 gene as the cause?
- Are you able to attend regular follow-up appointments for about a year?
What does participation involve?
If you decide to take part in this study, you would receive the CPK850 gene therapy administered directly into one of your eyes through a surgical procedure. This is a one-time treatment. After the treatment, you would have a series of visits to the clinic so the research team can carefully monitor your health and your vision.
During these visits, different tests would be carried out. These might include checking your eyesight, how well your eyes adapt to dark conditions, your ability to see colours, and asking you to fill out questionnaires about your vision and how it affects your daily life. You might also have scans or other tests to look at the health of your retina. The total duration of your participation, including all follow-up visits, would be up to a year, or potentially longer depending on the study plan.
Potential risks and benefits
Locations (1)
- —UnverifiedSweden
Common questions
What is retinitis pigmentosa?
It's an inherited eye disease that causes cells in the retina (at the back of your eye) to break down, leading to vision loss over time, especially in dim light.
What is CPK850 gene therapy?
It's an experimental treatment that aims to deliver a healthy version of the RLBP1 gene into the eye to help the light-sensing cells work better.
Why is this study important?
This is the first time this treatment is being tested in humans, so it helps us understand if it's safe and if it could be a future option for treating this specific type of retinitis pigmentosa.
Will my vision definitely improve?
While researchers hope to see improvements, this is an early-stage study primarily focused on safety. There's no guarantee that your vision will improve.
What does a 'responder in dark adaptation' mean?
It means the study will check if your ability to see in dim light improves noticeably for at least two visits within a year after treatment.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.